To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Vivos Therapeutics (NasdaqCM:VVOS) Q3 2025 Earnings Call November 19, 2025 05:00 PM ET Company ParticipantsBrad Amman - CFOKirk Huntsman - Chairman and CEOConference Call ParticipantsRobert Sassoon - Senior Research AnalystLucas Ward - Senior Research AnalystOperatorGood day, everyone, and welcome to the Vivos Third Quarter 2025 Conference Call. At this time, participants are in a listen-only mode. A question-and-answer session will follow the management's remarks. This conference call is being recorded, an ...

Vivos Therapeutics (NasdaqCM:VVOS) Q3 2025 Earnings Call November 19, 2025 05:00 PM ET Company ParticipantsBrad Amman - CFOKirk Huntsman - Chairman and CEOConference Call ParticipantsRobert Sassoon - Senior Research AnalystLucas Ward - Senior Research AnalystOperatorGood day, everyone, and welcome to the Vivos Third Quarter 2025 conference call. At this time, participants are in a listen-only mode. A question-and-answer session will follow the management's remarks. This conference call is being recorded, an ...

Vivos Therapeutics (NasdaqCM:VVOS) Q3 2025 Earnings Call November 19, 2025 05:00 PM ET Speaker0Good day, everyone, and welcome to the Vivos Third Quarter 2025 conference call. At this time, participants are in a listen-only mode. A question-and-answer session will follow the management's remarks. This conference call is being recorded, and the replay of today's call will be available on the Investor Relations section of Vivos' website and will remain posted there for the next 30 days. I will now hand the ca ...

Exhibit 99.1 Vivos Therapeutics Reports Significant Revenue Growth During the Third Quarter 2025 Financial results highlighted by 78% sequential quarter over quarter revenue growth, showing the impact of the first full quarter of Sleep Center of Nevada operations Management to host conference call today at 5:00 pm ET to review results and provide operational updates LITTLETON, Colo., November 19, 2025 – Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ: VVOS), a leading medical device and healthc ...

Financial results highlighted by 78% sequential quarter over quarter revenue growth, showing the impact of the first full quarter of Sleep Center of Nevada operations Management to host conference call today at 5:00 pm ET to review results and provide operational updates LITTLETON, Colo., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and healthcare services company specializing in the delivery of highly effective diagnostic pr ...

FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 7921 Southpark Plaza, Suite 210, Littleton, CO 80120 (Address of principal executive offices) (Zip Code) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2025 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-39796 Vivos Therap ...

Call scheduled for today, Wednesday, November 19, 2025, at 5:00 pm ETLITTLETON, Colo., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and healthcare services company specializing in the delivery of highly effective diagnostic procedures and proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults and moderate to severe OSA in children), today announced it p ...

会议基本信息 - 本次会议为Vivos Therapeutics公司2025年度股东大会 通过线上直播方式举行 [1] - 公司首席执行官兼董事会主席R Huntsman主持会议 首席财务官Brad Amman担任会议秘书 [2] - 董事会成员 公司员工及外部法律顾问以只听模式参会 [2] 会议参与方式 - 会议采用虚拟股东会议形式 旨在提高参与便利性和出席率 [3] - 所有在2025年9月8日登记在册的股东均有资格通过代理或虚拟方式投票 [3] - 已提交代理投票的股东无需再次投票 但登记持有人未提交代理或希望更改投票可获取代理卡 [4]

文章核心观点 - Vivos公司发布新的临床数据 证实其DNA设备可安全有效地治疗儿童阻塞性睡眠呼吸暂停（OSA）并显著改善注意力缺陷/多动障碍（ADHD）症状 [1] - DNA设备是唯一获得FDA 510k批准、针对6-17岁儿童中重度OSA的非手术非药物疗法 被视为腺样体扁桃体切除术的可行替代方案 [2] - 通过治疗OSA ADHD症状可大幅减少或消除 临床数据显示PSQ评分降低50% ADHD相关症状降低58% [5][6] 疾病流行病学与市场背景 - 美国ADHD诊断率自1980年代约2-3%大幅上升至2022年超11% 学龄儿童患者约710万（约每9名儿童中有1名）[3][4] - 儿童OSA患病率从2014年前3-9%上升至2022年13-20% 高达95%的儿科OSA患者报告存在注意力缺陷 [3][4] - OSA与ADHD在儿科人群中存在双向关联和症状重叠 导致OSA患儿常被误诊为ADHD [3] 临床数据结果 - 治疗组儿童经验证的儿科睡眠问卷（PSQ）评分显示打鼾、睡眠呼吸暂停和不宁腿症状降低50% (p<0.00001) [6] - 睡眠呼吸紊乱和ADHD症状（如破坏性行为和多动）降低58% OSA严重程度（根据AHI评分）降低51.4% [6][7] - 100%患者腭宽度增加13.6% 气道容积增加40% 所有改善均具有统计学显著性 [7] - 48名患者完成临床试验（原55名） 平均年龄10.6岁 包括28名男性和20名女性 [7] 产品与市场定位 - Vivos的CARE系列设备是唯一获FDA批准治疗成人重度OSA及儿童中重度OSA的技术 [9][10] - 公司瞄准通过非手术非药物方法治疗儿童OSA以解决ADHD症状的巨大未开发市场 [5] - 全球OSA患者超10亿 但90%未得到诊断 传统疗法如CPAP未能解决根本原因 儿童手术效果随时间减弱 [11] 公司背景与战略 - Vivos成立于2016年 专注于开发治疗因牙面异常引起的呼吸和睡眠问题的创新诊断和治疗方法 [9][12] - 通过技术、教育及收购或商业合作 赋能医疗提供商更全面解决OSA患者复杂需求 [12] - Vivos方法提供专有、临床有效的非手术非侵入性非药物解决方案 [13]